User Settings
Open AccessArticle10.1080/08998280.2011.11928729

Recombinant Tissue Plasminogen Activator for the Treatment of Acute Ischemic Stroke

Jennifer Roth-2011-07-01-Baylor University Medical Center Proceedings
75PDF

TL;DRAbstract

The use of recombinant tissue plasminogen activator (rtPA) has been the standard of care for treatment of acute ischemic stroke for several years. Studies evaluating the efficacy, safety, and optimal timing of rtPA use are ongoing. Recently, results of new studies led to expansion of the short timeframe from stroke symptom onset in which a patient can receive this treatment. Additionally, more data are available to support the current goals of administration of rtPA to eligible patients as quickly as possible, as earlier treatment has been proven to improve outcomes.

Chat with Paper

AI Agents for this Paper

The use of recombinant tissue plasminogen activator (rtPA) has been the standard of care for treatment of acute ischemic stroke for several years. Studies evaluating the efficacy, safety, and optimal timing of rtPA use are ongoing. Recently, results of new studies led to expansion of the short timeframe from stroke symptom onset in which a patient can receive this treatment. Additionally, more data are available to support the current goals of administration of rtPA to eligible patients as quickly as possible, as earlier treatment has been proven to improve outcomes.

Keywords

Recombinant tissue plasminogen activatorMedicineTissue plasminogen activatorStroke (engine)Ischemic strokeT-plasminogen activatorPlasminogen activatorIntensive care medicine

Chat

Click to start Chat